The path to find an HIV vaccine.

This strategy was broken into two frameworks: I the first i to determine whether broadly protective antibodies could reduce HIV acquisition, that is could a vaccine regimen that elicited high levels of non-neutralizing antibodies be developed that would enhance the protective efficacy beyond that seen in RV144; I and second i , to discern whether neutralizing antibodies could actually prevent acquisition. HIV vaccine development has become a process of stepwise learning of how to make a vaccine that induces an immune response that is markedly better than the human immune response to HIV. Keywords: HIV vaccine; clinical trials; broadly neutralizing antibodies EN HIV vaccine clinical trials broadly neutralizing antibodies 1 3 3 06/05/21 20210501 NES 210501 Since the discovery that a retrovirus, human immunodeficiency virus type one (HIV-1), causes the acquired immune deficiency syndrome (AIDS), more than 77 million people have become infected with HIV and 37 million have died over the last 40 years [1]. Essentially the inability to elicit broadly neutralizing antibodies to HIV to cover its strain diversity has been a major flaw in the HIV vaccine field for the first 30 years of vaccine development. [Extracted from the article]